Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 15 years ago, it would be worth $681.19 today based on a price of $112.09 for GILD at the time of writing.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ: GILD) ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effec ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...